Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this research is to evaluate and compare the effectiveness of Systane® versus Optive™ on aqueous tear film stability in patients with a diagnosis of Dry Eye Syndrome and to determine the possible application for this product in the future. Systane® is marketed as over-the-counter tear lubricating therapy in the United States under the FDA monograph.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: Investigator initiated study

Criteria

Inclusion Criteria:

• Individuals aged 18 and up will be included, where any age over 89 will be recorded as 'greater than 89.'

• Individuals with bilateral eye sight eye correctable to 20/80 or better.

• Individuals in good health with or without Meibomian Gland Dystrophy (MGD) but with Aqueous Tear Deficiency (ATD) with minimal to no ocular surface inflammation on slit lamp examination.

Exclusion Criteria:

• Individuals with only one sighted eye or vision not correctable to 20/80 or better in both eyes.

• Individuals with history of punctal plugs or punctal occlusions.

• Individuals with history of keratorefractive as well as ophthalmic disease such as corneal dystrophies, glaucoma, or systemic disease affecting the eye (such as Herpes Zoster).

• Individuals with history of systemic or ocular auto-immune conditions.

• Individuals with active systemic disease or those taking systemic medication that are known to influence AT production will not be considered for this trial.

• Individuals using topical medication who are unable to discontinue them for at least 24 hours prior to baseline evaluation will be excluded as well.